You are here:

micafungin (Mycamine)

Advice

Following a full submission

micafungin (Mycamine®) is accepted for restricted use within NHS Scotland. It is restricted to use in the treatment of invasive candidiasis in adults, elderly, and children (including neonates). Micafungin has been shown to be non-inferior to caspofungin and liposomal amphotericin B in the treatment of patients with invasive candidiasis, the majority of whom had candidaemia and were non-neutropenic. It was effective in the treatment of both C. albicans and non-albicans Candida species.

micafungin (Mycamine®) is not recommended for use within NHS Scotland for the treatment of oesophageal candidiasis in adult, elderly, and adolescent (16 years of age) patients for whom intravenous therapy is appropriate. The manufacturer did not supply any economic analysis and therefore the cost effectiveness could not be assessed.

micafungin (Mycamine®) is not recommended for use within NHS Scotland for prophylaxis of Candida infection in adults, elderly, and children (including neonates) undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days. The manufacturer did not supply any economic analysis and therefore the cost effectiveness could not be assessed.

Drug Details

Drug Name: micafungin (Mycamine)
SMC Drug ID: 497/08
Manufacturer: Astellas Pharma Ltd
Indication: for the treatment of invasive candidiasis
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 September 2008

Back